Who Paid My Doc
John Paschold
Williamsburg, VA Medical Doctor
NPI 1962407510 CMS profile 1308205
500 Sentara Circle, Suite 203, Williamsburg, VA 23188
General payments
$6,063
Research payments
$5,700
Ownership & investment interest
$0
Research they led as principal investigator
$867,222
Through program year 2025, John Paschold of Williamsburg, VA is reported in the CMS Open Payments database as having received $6,063 across 18 general payments and $5,700 in research payments paid to them. Separately, studies naming them as principal investigator received $867,222 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,628 | 4 | |
| 2023 | General | $1,031 | 2 | |
| 2022 | General | $1,952 | 1 | |
| 2022 | Research | $5,700 | 9 | |
| 2021 | General | $220 | 3 | |
| 2020 | General | $1,171 | 4 | |
| 2019 | General | $59 | 4 |
Beside peers
- John Paschold
- Virginia median
- Middle half of Virginia
- National median
In program year 2025, general payments to John Paschold were reported at $1,628. Among 24,845 Virginia profiles paid that year, the median was $179 and the middle half received between $56 and $613.
Show as a table
| Year | John Paschold | Virginia median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $59 | $162 | $50–$582 | $163 |
| 2020 | $1,171 | $111 | $36–$367 | $114 |
| 2021 | $220 | $125 | $37–$450 | $132 |
| 2022 | $1,952 | $149 | $45–$527 | $149 |
| 2023 | $1,031 | $161 | $50–$554 | $160 |
| 2024 | $0 | $171 | $55–$585 | $164 |
| 2025 | $1,628 | $179 | $56–$613 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
385
Drug cost
$1,911,996
Branded share of claims
56.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | Brand | 48 | $723,011 | |
| Pomalyst Pomalidomide | Brand | 21 | $479,388 | |
| Promacta Eltrombopag Olamine | Brand | 11 | $269,374 | |
| Imbruvica Ibrutinib | Brand | 12 | $197,081 | |
| Brukinsa Zanubrutinib | Brand | 12 | $169,400 | |
| Xarelto Rivaroxaban | Brand | 42 | $39,618 | |
| Eliquis Apixaban | Brand | 61 | $32,864 | |
| Dexamethasone | Generic | 35 | $415 | |
| Oxycodone Hcl | Generic | 12 | $235 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 12 | $204 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 184 billing codesPaid by Medicare
$2,495,271
Medicare patients
622
Services billed
110,836
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 48% | |
| Cancer | 47% | |
| Diabetes | 34% | |
| Chronic kidney disease | 34% | |
| Ischemic heart disease | 32% | |
| Heart failure | 27% | |
| COPD | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 28 | 19,900 | $777,218 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 11 | 5,220 | $204,755 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 | Office | 21 | 9,300 | $21,540 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg J2506 | Office | 12 | 216 | $14,249 |
| Injection, pemetrexed, 10 mg J9305 | Office | 11 | 2,490 | $8,814 |
| Injection, iron dextran, 50 mg J1750 | Office | 22 | 508 | $7,004 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram Q5110 | Office | 12 | 7,380 | $1,630 |
| Injection, carboplatin, 50 mg J9045 | Office | 17 | 253 | $670 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 21 | 5,700 | $633 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 40 | 830 | $590 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
27 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.